The average one-year price target for Genmab A (NasdaqGS:GMAB) has been revised to $55.27 / share. This is a decrease of ...

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market ...

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, ...

Danish biotech Genmab reported a 25% rise in its total revenue to $1.02 billion during the third quarter of 2025, ahead of ...

November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab's proposed acquisition of Merus N.V. (Merus)Genmab revenue increased ...

Genmab ( ($GMAB) ) has issued an announcement. On November 6, 2025, Genmab announced its financial results for the first nine months of 2025, ...

Genmab A/S(Nasdaq: GMAB)today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell ...

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes ...

Investing.com - H.C. Wainwright has reiterated its Buy rating and $40.00 price target on Genmab A/S (NASDAQ:GMAB), a company currently rated ’EXCELLENT’ by InvestingPro’s comprehensive health score ...